Phico Therapeutics appoints Financial Director and two Non-Executives
Senior management team and Board strengthened with Andrew Armour joining as Financial Director, and Professor Mark Wilcox and David Beadle as Non-Executive Directors
CAMBRIDGE, UK, 15 January 2019 – Phico Therapeutics Ltd (‘Phico’), a biotechnology company developing a novel platform technology as the basis of a new generation of antibiotics to overcome antibacterial resistance, has announced the appointment of Andrew Armour as Financial Director (FD), and Professor Mark Wilcox and David Beadle as Non-Executive Directors (NEDs). The appointments have been made to support the progression of Phico’s lead product SASPject™ PT3.8 through clinical trials, and the financing of the Company’s planned clinical-grade manufacturing facility.
Full PR available here